CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01950390
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:51.015230+00:00
Published At: 2024-04-25T00:00:00+00:00
Record Updated At: 2025-12-11
Results Posted At: 2024-04-25
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Unresectable Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-11"
protocolSection.identificationModule.nctId: "NCT01950390"
protocolSection.identificationModule.officialTitle: "A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-04-25"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.